F
Frank Hartmann
Researcher at Saarland University
Publications - 54
Citations - 4262
Frank Hartmann is an academic researcher from Saarland University. The author has contributed to research in topics: Antigen & Monoclonal antibody. The author has an hindex of 25, co-authored 48 publications receiving 3981 citations.
Papers
More filters
Journal ArticleDOI
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh,Joerg Schubert,Marita Ziepert,Rudolf Schmits,Martin Mohren,Eva Lengfelder,Marcel Reiser,Christina Nickenig,Michael R. Clemens,Norma Peter,Carsten Bokemeyer,Hartmut Eimermacher,Anthony D. Ho,Martin Hoffmann,Roland Mertelsmann,Lorenz Trümper,Leopold Balleisen,Ruediger Liersch,Bernd Metzner,Frank Hartmann,Bertram Glass,Viola Poeschel,Norbert Schmitz,Christian Ruebe,Alfred C. Feller,Markus Loeffler +25 more
TL;DR: In a multivariate analysis that used six cycles of CHOP-14 without rituximab as the reference, and adjusting for known prognostic factors, all three intensified regimens improved 3-year event- free survival and progression-free survival.
Journal ArticleDOI
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Roswitha Forstpointner,Martin Dreyling,Roland Repp,Sandra Hermann,A. Hänel,Bernd Metzner,Christiane Pott,Frank Hartmann,Frank Rothmann,Robert Rohrberg,Hans-Peter Böck,Hannes Wandt,Michael Unterhalt,Wolfgang Hiddemann +13 more
TL;DR: In this article, a prospective randomized study in patients with relapsed disease showed that the addition of rituximab to FCM chemotherapy significantly improves the outcome of relapsed or refractory FL and mantle cell lymphoma (MCL).
Journal ArticleDOI
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Roswitha Forstpointner,Michael Unterhalt,Martin Dreyling,Hans-Peter Böck,Roland Repp,Hannes Wandt,Christiane Pott,John F. Seymour,Bernd Metzner,A. Hänel,Tanja Lehmann,Frank Hartmann,Hermann Einsele,Wolfgang Hiddemann +13 more
TL;DR: R-maintenance is effective after salvage with R-chemotherapy and significantly prolongs response duration in patients with recurring or refractory FL or MCL, and was observed when analyzing FL and MCL separately.
Journal ArticleDOI
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Ralf Hofheinz,Salah-Eddin Al-Batran,Frank Hartmann,G. Hartung,Dirk Jäger,Christoph Renner,P. Tanswell,U. Kunz,A. Amelsberg,H. Kuthan,G. Stehle +10 more
TL;DR: Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics and was well tolerated and safe.
Journal ArticleDOI
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Richard F. Schlenk,Konstanze Döhner,Michael Kneba,Katharina Götze,Frank Hartmann,Francesco del Valle,Heinz Kirchen,Elisabeth Koller,J. T. Fischer,Lars Bullinger,Marianne Habdank,Daniela Späth,Silja Groner,Bernhard Krebs,Sabine Kayser,Andrea Corbacioglu,Andreas Anhalt,Axel Benner,Stefan Fröhling,Hartmut Döhner +19 more
TL;DR: In elderly patients with acute myeloid leukemia, NPM1 mutations are associated with achievement of complete remission, and the genotype ‘mutant N PM1 without FLT3-ITD’ appears to be a predictive marker for response to all-trans retinoic acid given as an adjunct to intensive chemotherapy.